# Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

> **NCT05709171** · PHASE2 · UNKNOWN · sponsor: **Rigshospitalet, Denmark** · enrollment: 200 (estimated)

## Conditions studied

- GEP-NET
- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- Neuroendocrine Carcinoma Metastatic

## Interventions

- **DRUG:** 18F-FDG
- **DRUG:** 64Cu-Dotatate

## Key facts

- **NCT ID:** NCT05709171
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-17
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05709171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05709171, "Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05709171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*